JP2000511529A5 - - Google Patents

Download PDF

Info

Publication number
JP2000511529A5
JP2000511529A5 JP1997542424A JP54242497A JP2000511529A5 JP 2000511529 A5 JP2000511529 A5 JP 2000511529A5 JP 1997542424 A JP1997542424 A JP 1997542424A JP 54242497 A JP54242497 A JP 54242497A JP 2000511529 A5 JP2000511529 A5 JP 2000511529A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997542424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000511529A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/007650 external-priority patent/WO1997045403A1/en
Publication of JP2000511529A publication Critical patent/JP2000511529A/ja
Publication of JP2000511529A5 publication Critical patent/JP2000511529A5/ja
Ceased legal-status Critical Current

Links

JP09542424A 1996-05-31 1997-05-12 選択的ドーパミンd3リガンドとしてのアリール置換環式アミン Ceased JP2000511529A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1879496P 1996-05-31 1996-05-31
US60/018,794 1996-05-31
PCT/US1997/007650 WO1997045403A1 (en) 1996-05-31 1997-05-12 Aryl substituted cyclic amines as selective dopamine d3 ligands

Publications (2)

Publication Number Publication Date
JP2000511529A JP2000511529A (ja) 2000-09-05
JP2000511529A5 true JP2000511529A5 (enExample) 2005-01-13

Family

ID=21789817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09542424A Ceased JP2000511529A (ja) 1996-05-31 1997-05-12 選択的ドーパミンd3リガンドとしてのアリール置換環式アミン

Country Status (21)

Country Link
US (1) US6084130A (enExample)
EP (1) EP0923542B1 (enExample)
JP (1) JP2000511529A (enExample)
KR (1) KR20000016147A (enExample)
CN (1) CN1159292C (enExample)
AT (1) ATE247639T1 (enExample)
AU (1) AU720414B2 (enExample)
CA (1) CA2255612A1 (enExample)
CZ (1) CZ370198A3 (enExample)
DE (1) DE69724259T2 (enExample)
DK (1) DK0923542T3 (enExample)
ES (1) ES2205227T3 (enExample)
FI (1) FI982572A7 (enExample)
NO (1) NO314398B1 (enExample)
NZ (1) NZ332538A (enExample)
PL (1) PL187296B1 (enExample)
PT (1) PT923542E (enExample)
RU (1) RU2185372C2 (enExample)
SI (1) SI0923542T1 (enExample)
SK (1) SK282725B6 (enExample)
WO (1) WO1997045403A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022230A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
DK1257527T3 (da) * 2000-02-22 2004-01-12 Upjohn Co (2S)-Aminoindanderivater, en fremgangsmåde til deres præparation og deres anvendelse som selektive dopamin-D3-ligander
AU2001288329A1 (en) 2000-09-18 2002-04-02 Pharmacia Ab Process to prepare (2s)-2-(dipropylamino)-6-ethoxy-2,3-dihydro-1h-indene-5- carboxamide
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
EP1495004A2 (en) * 2002-02-13 2005-01-12 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor ligands
JP4594386B2 (ja) * 2004-06-02 2010-12-08 エフ.ホフマン−ラ ロシュ アーゲー ヒスタミン3受容体のリガンドとして有用なナフタレン誘導体
JP5193602B2 (ja) * 2004-10-14 2013-05-08 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンd3受容体の調節に応答する障害の治療に好適なアリールスルホニルメチルまたはアリールスルホンアミド置換芳香族化合物
MX2007004358A (es) 2004-10-14 2007-07-17 Abbott Gmbh & Co Kg Compuestos de azabicicloheptilo adecuados para tratar trastornos que responden a la modulacion del receptor de dopamina d3.
MX2007004354A (es) * 2004-10-14 2007-07-17 Abbot Gmbh & Co Kg Compuestos aromaticos biciclicos sustituidos con aminometilo adecuados para tratar trastornos que responden a la modulacion del receptor de dopamina d3.
EP2371814A1 (en) * 2004-10-14 2011-10-05 Abbott GmbH & Co. KG Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
NZ555121A (en) 2004-10-14 2011-01-28 Abbott Gmbh & Co Kg 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 recptor
EP2311803A1 (en) 2004-10-14 2011-04-20 Abbott GmbH & Co. KG Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
AU2006259294A1 (en) * 2005-06-17 2006-12-28 Wyeth Tricyclic compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists
US20080262228A1 (en) * 2006-11-28 2008-10-23 Wyeth Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof
GB0721333D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
GB0721332D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
CN102786483B (zh) * 2011-05-19 2016-03-30 复旦大学 4-(4-苯基哌嗪基)喹唑啉类衍生物的药用用途
EP3174853B1 (en) * 2014-07-30 2018-12-12 F.Hoffmann-La Roche Ag 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives as taar modulators
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
CN110041318B (zh) * 2018-01-17 2022-07-29 中国科学院上海药物研究所 一类多巴胺d5受体激动剂及其制备和应用
CA3093851A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma Corporation Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2752659A1 (de) * 1976-12-07 1978-06-08 Sandoz Ag Neue tetralinderivate, ihre herstellung und verwendung
FR2512814A1 (fr) * 1981-09-16 1983-03-18 Synthelabo Derives d'amino-2 tetrahydro-1,2,3,4 naphtalene, leur preparation et leur application en therapeutique
US4448990A (en) * 1982-11-16 1984-05-15 Eli Lilly And Company Hydroxyaminotetralincarboxamides
JPS6169747A (ja) * 1984-08-31 1986-04-10 Otsuka Pharmaceut Co Ltd 2,3―ジヒドロ―1h―インデン誘導体及びその製造法
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US5225596A (en) * 1989-01-09 1993-07-06 The Upjohn Company Halo substituted aminotetralins
DK0690843T3 (da) * 1993-03-25 2000-11-13 Upjohn Co Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet
AU7513494A (en) * 1993-08-06 1995-02-28 Upjohn Company, The 2-aminoindans as selective dopamine d3 ligands
ES2159017T3 (es) * 1995-02-01 2001-09-16 Upjohn Co 2-aminoindanos como ligandos selectivos de la dopamina d3.
US6008219A (en) * 1995-03-27 1999-12-28 Smithkline Beech P.L.C. Bicyclic amine derivatives and their use as anti-psychotic agents

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000501324A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2001506378A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2001505048A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)